Jill Feldman, co-founder of the EGFR Resisters, presented on Diversifying Clinical Trial Inclusion Criteria: Currrent Challenges and Potential Solutions to help ensure every decision, starting at concept is looked at through a health equity lens. Creating clinical trials WITH us not just FOR us! It is a moral imperative of including the patient voice in clinical trial design to achieve justice in health care delivery. Watch the video here or read the transcript.
We are a group of lung cancer patients with EGFR mutations who have developed resistance to at least one targeted treatment drug, or who face probable resistance in the future. Caregivers are also welcome. We are here to share treatment experiences, information about clinical trials, breaking news about research developments, and other information with each other.